Construction and characterization of a Pseudomonas aeruginosa mucoid exopolysaccharide-alginate conjugate vaccine

Christian Theilacker1, Fadie T Coleman, Simone Mueschenborn

  • 1Channing Laboratory, Department of Medicine, Harvard Medical School, Boston, Massachusetts 02115-5804, USA.

Insights

Conjugating mucoid exopolysaccharide (MEP) from Pseudomonas aeruginosa to a carrier protein (KLH) significantly boosts the immune response, generating protective opsonic antibodies crucial for fighting CF lung infections.

Area of Science:

  • Immunology
  • Microbiology
  • Vaccine Development

Background:

  • Cystic Fibrosis (CF) lung function decline is linked to chronic Pseudomonas aeruginosa infection.
  • Mucoid exopolysaccharide (MEP) from P. aeruginosa can induce protective opsonic antibodies, but its direct use in vaccines is minimally effective.

Purpose of the Study:

  • To enhance the immunogenicity of MEP by conjugating it to a carrier protein (KLH).
  • To evaluate the efficacy of the MEP-KLH conjugate in inducing opsonic antibodies against mucoid P. aeruginosa.

Main Methods:

  • Thiolated MEP was conjugated to keyhole limpet hemocyanin (KLH) using SMCC linker.
  • Immunogenicity and opsonic activity of the MEP-KLH conjugate were assessed in mice and rabbits.
  • The impact of pre-existing antibodies on the immune response was investigated.

Main Results:

  • MEP-KLH conjugate induced high titers of MEP-specific IgG and significant opsonic killing activity in mice and rabbits.
  • The conjugate elicited broadly cross-reactive opsonic antibodies against heterologous mucoid P. aeruginosa strains.
  • Antibodies targeting O-acetate residues on MEP were identified as mediating opsonic killing.

Conclusions:

  • Conjugation of MEP to KLH dramatically improves its immunogenicity and ability to elicit protective opsonic antibodies.
  • The MEP-KLH conjugate vaccine is effective in inducing opsonic antibodies, even in the presence of pre-existing non-opsonic antibodies.
  • Targeting acetate residues on MEP holds promise for developing effective vaccines against mucoid P. aeruginosa infections in CF patients.